Nimodipine Capsules 30 mg, Rx Only, For Institutional Use Only, a) 30-count unit dose Capsules (5x6 blister cards per carton), NDC 57664-135-64, b) 100-count unit dose Capsules (25x4 blister cards per carton), NDC 57664-135-65, Distributed by: Caraco Pharmaceutical Laboratories, Ltd. Detroit, MI 48202 Affiliate of Sun Pharmaceutical Industries, Inc.

Class I - Dangerous

What Should You Do?

  1. Check if you have this product:
    Lot: a) 3305.039B, Exp 07/13; b) 3305.039A, Exp 07/13
  2. Do not eat it: Even if it looks and smells fine, do not consume this product.
  3. Throw it away or return it: You can return the product to the store for a full refund.
  4. Seek medical attention if needed: If you've consumed this product and feel unwell, contact your doctor immediately.
  5. Report problems: Report any issues to the FDA's Safety Reporting Portal.

⚠️ Emergency: If you experience severe symptoms after consuming this product, call 911 or Poison Control at 1-800-222-1222.

Recall Details

Company:
Caraco Pharmaceutical Laboratories Ltd.
Reason for Recall:
Crystallization: Presence of crystals of Nimodipine within the capsule solution.
Classification:
Class I - Dangerous

Dangerous or defective products that predictably could cause serious health problems or death.

Status:
terminated

Product Information

Full Description:

Nimodipine Capsules 30 mg, Rx Only, For Institutional Use Only, a) 30-count unit dose Capsules (5x6 blister cards per carton), NDC 57664-135-64, b) 100-count unit dose Capsules (25x4 blister cards per carton), NDC 57664-135-65, Distributed by: Caraco Pharmaceutical Laboratories, Ltd. Detroit, MI 48202 Affiliate of Sun Pharmaceutical Industries, Inc.

Product Codes/Lot Numbers:

Lot: a) 3305.039B, Exp 07/13; b) 3305.039A, Exp 07/13

Official Source

Always verify recall information with the official FDA source:

View on FDA.gov

FDA Recall Number: D-003-2013

Related Recalls

CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

Jun 26, 2014 Prescription Drugs Nationwide View Details →

CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

Jun 26, 2014 Prescription Drugs Nationwide View Details →

Failed Dissolution Specifications: Stability results found the product did not meet the drug dissolution specifications.

Jun 12, 2014 Prescription Drugs Nationwide View Details →